The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC)
- 21 August 2025
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 66 (4) , 2500287
Abstract
Background: The microbiome is associated with exacerbation risk, quality of life and mortality in COPD. Inhaled corticosteroid (ICS) treatment has been reported to alter the microbiome through modulating host defence. How ICS alters the microbiome and whether effects are equal between different ICS preparations is debated. The aim of the MUSIC trial was to investigate whether commonly used ICS therapies have different effects on the airway microbiome in COPD. Methods: This was a multicentre randomised controlled trial. After a 4-week washout period during which they withdrew from ICS, patients with COPD (forced expiratory volume in 1 s versus FS500, with sputum bacterial load the key secondary end-point. Results: 122 participants started the washout period. ICS withdrawal was poorly tolerated; 61 participants withdrew before randomisation with 45 experiencing an exacerbation. 61 patients were randomised. No statistically significant differences were observed for the primary comparison of BF400 versus FS500 in oropharyngeal bacterial load. There was, however, a significant increase in sputum bacterial load with FS500 compared to BF400 by month 3. This difference was not seen with FS250. No significant differences in microbiome α-diversity were observed over time. Adverse events were similar between the groups. Conclusion: FS500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD.Keywords
Funding Information
- AstraZeneca
This publication has 35 references indexed in Scilit:
- Streptococcus pneumoniae as a colonizing agent of the Nasopharynx - Oropharynx in adults: A systematic review and meta-analysisVaccine, 2024
- Inhaled corticosteroid suppression of cathelicidin drives dysbiosis and bacterial infection in chronic obstructive pulmonary diseaseScience Translational Medicine, 2019
- Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trialRespiratory Medicine, 2017
- Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPDNew England Journal of Medicine, 2014
- Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting 2 agonist: observational matched cohort study (PATHOS)BMJ, 2013
- Inhaled corticosteroids increase the risk of oropharyngeal colonization by Streptococcus pneumoniae in children with asthmaRespirology, 2012
- Budesonide and risk of pneumoniaThe Lancet, 2009
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007
- Streptococcus pneumoniae colonisation: the key to pneumococcal diseaseThe Lancet Infectious Diseases, 2004
- Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitisThe American Journal of Medicine, 2000